I’ve been thinking about this, so I asked Grok whether he thought we’d be better off …
“Redomiciling to Nasdaq could juice Mesoblast’s share price long-term by tapping U.S. biotech mania—think $25+ if all goes well. But short-term, watch for an ASX sell-off dip before the U.S. crowd takes over. It’s a gamble on whether Nasdaq’s depth drowns out the manipulation you’ve spotted on the ASX—or just shifts it overseas.”
Ann: ZSP: Arcadium Lithium PLC to be removed from the S&P/ASX 200, page-124
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
0.015(0.93%) |
Mkt cap ! $2.079B | |||
| Open | High | Low | Value | Volume |
| $1.60 | $1.66 | $1.60 | $5.944M | 3.647M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 33055 | $1.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 14062 | 4 |
View Market Depth
| Last trade - 15.59pm 26/06/2025 (20 minute delay) ? |
| MSB (ASX) Chart |